Houston Tech Rodeo returns with 2023 programing across space, health, emerging tech, and more. Image via houstontechrodeo.com

Houston Tech Rodeo returns this year — and the lineup of panels and networking opportunities has been released online.

The four-day summit was originally introduced in 2020 by Houston Exponential to shine a spotlight on Houston's tech and startup ecosystem. Last year, HX changed ownership, converted into a for-profit business, and named Natara Branch as the new CEO. With the new ownership comes a new era for HTR — complete with AI-generated media, a goal for a record-breaking finale event with CodeLaunch, and more.

"The biggest theme of Tech Rodeo this year is around being aware," Branch tells InnovationMap. "We want entrepreneurs to know what resources are out there, that they are supported, and that there are all these entities out here that are conducting themselves in a manner that is really centered around supporting them."

"We hope that when entrepreneurs and startups walk away from Tech Rodeo this year, it will really feel to them like there's more momentum in this city than there has been in the past so that we can be a top-tier startup destination," she continues.

This year's schedule is divided across a few themes and all events are being held in the Houston Innovation District in Midtown.

  • Monday, February 27: Space Tech at the Ion
  • Tuesday, February 28: Global Mindset at HCC Central Campus and Energy Tech at Greentown Labs
  • Wednesday, March 1: Bio Economy at TMC Innovation and Emerging Tech at The Cannon - Downtown
  • Thursday, March 2: Townhall and CodeLaunch Finale at Sesh Coworking and 713 Music Hall
The week's events will attract founders, investors, startup development organizers, and more. When HTR launched its free tickets online, Branch says they received around 800 registrants in one day. At the center of everything HX does is the Houston founders, Branch says.
"It was supper important to us to make sure that entrepreneurs have access," she says. "It's free to entrepreneurs — they are number one in who should attend."

More information and registration is available at houstontechrodeo.com.

Head to houstontechrodeo.com for up-to-date schedule information. Graphic courtesy of HX

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.